CA-BIOCELL-TECHNOLOGY
13.6.2019 02:53:04 CEST | Business Wire | Press release
BioCell Technology, LLC, a branded dietary ingredient supplier, today announced the presentation of The Effects of Skin Aging Associated with the Use of BioCell Collagen® in Healthy Adult Females: A Randomized, Double-blind, Placebo-controlled Clinical Trial . These results were presented in a poster session at the American Society for Nutrition (ASN) Nutrition 2019 on June 9, 2019, and are available at http://bit.ly/2WzhODi . This poster will be published as part of the proceedings of Nutrition 2019 by ASN. The manuscript of the study will be published in the online and print versions of the peer review journal Alternative Therapies in Health and Medicine (ATHM).
The goal of the study was to determine if a correlation existed between the effects of the dietary supplement, BioCell-Collagen®, with changes associated with skin aging. The study was a 128-female subject, 12-week, double-blind, placebo-controlled trial. Participants were randomly assigned to an intervention or a placebo. The intervention consisted of twice daily 500mg oral administration of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract dietary ingredient composed of a naturally-occurring matrix of collagen type-II peptides (≥300 mg), chondroitin sulfate (≥100 mg), and hyaluronic acid (≥50 mg).
For the 113 participants completing the study, BioCell Collagen® supplementation compared to a placebo resulted in:
- Significantly reduced facial lines and wrinkles (P = .019) and crow’s feet lines and wrinkles (P = .05)
- Increased skin elasticity (P = .008) and cutaneous collagen content (P < .001) by 12%
- Improved indicators associated with a more youthful skin appearance based on visual grading and wrinkle width (P = .046)
- Decreased skin dryness and erythema.
- No difference existed between the supplement and the placebo for skin surface water content or retention. The supplement was well tolerated, with no reported adverse reactions.
“We are very excited to publish the findings of our largest study to date, which further supports the efficacy of our flagship dietary ingredient BioCell Collagen®. Human clinical studies continue to be the gold standard for substantiating dietary supplement claims and we take pride that our licensed partners can take advantage,” said Suhail Ishaq, president of BioCell Technology.
The latest study validates an earlier pilot study that demonstrated similar results- Schwartz SR, Park J. Ingestion of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial aging signs. Clin Interven Aging . 2012; 7: 267-273.
“An impressive example of how a series of studies, capped by a randomized, double-blind, placebo-controlled, supports a ‘beauty from within’ claim in healthy women. Even more impressive was that the results remained statistically significant even after an intention-to-treat analysis was performed that included the few subjects that dropped out of the study. Such an analysis is seen in only about 15-20% of randomized, placebo-controlled blinded clinical studies published in leading medical journals,” said Alexander Schauss, PhD, FACN, CFS, Senior Director of Research at AIBMR Life Sciences, and the corresponding author.
“It is important that the supplement industry conducts research at the pinnacle of good science and this includes a double blind, properly populated study like this one,” said Stephen Schwartz, President and CEO of International Research Services, Inc.
About BioCell Collagen ®
BioCell Collagen® is a clinically tested branded dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials, including trials on safety, efficacy, and bioavailability. BioCell Collagen® is self-affirmed GRAS (Generally Recognized As Safe). BioCell Collagen® is non-GMO and free of gluten, soy, shellfish, fish, egg, milk, peanuts and sugar. BioCell Collagen® is made exclusively in the USA and Europe. For more information, visit www.BioCellCollagen.com .
About BioCell Technology, LLC
BioCell Technology is a research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information visit www.BioCellTechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005972/en/
Contact:
Suhail Ishaq President of BioCell Technology, LLC 714-632-1231
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces Amendment to Maximize Size of Normal Course Issuer Bid9.3.2026 12:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that, further to its previously announced intention to maximize the size of its normal course issuer bid (the “NCIB”), it has received approval from the Toronto Stock Exchange (the “TSX”) to amend (the “Amendment”) the NCIB, effective on March 11, 2026 (the “Effective Date”), to increase the maximum number of common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, the maximum amount allowable under the rules of the TSX. No other terms of the NCIB have been amended. The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million. In its February 4, 2026
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”9.3.2026 10:53:00 CET | Press release
Ki Reply and Data Reply, the Reply Group companies specialised respectively in AI-powered software development and data-driven solutions, have partnered with the “CRM Excellence” department of medical technology company Siemens Healthineers to develop “Cerebra“, an advanced AI platform designed to deliver rapid, relevant insights across marketing and sales. The concept proved so successful that “Cerebra” was evolved into an Agent Factory, which now standardises, simplifies, and accelerates the deployment of AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309083025/en/ To support labour-intensive manual research in marketing, and sales, Siemens Healthineers now leverages “Cerebra“, an AI-powered knowledge platform that uses specialised AI agents to consolidate internal and external data. In the fast-moving and highly regulated medical technology market, the ability to analyse information accurately and quickly is
AMINA Becomes First Regulated Bank on 21X, Europe’s First Fully Regulated DLT Trading and Settlement Venue9.3.2026 08:30:00 CET | Press release
Along with Tokeny, the combined tokenisation suite creates a complete tokenisation infrastructure, from regulated custody to onchain trading and settlement AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today announces it has become a listing sponsor on 21X, the first fully regulated distributed ledger technology trading and settlement system (DLT TSS) in the European Union. AMINA is the first regulated bank to join the 21X ecosystem as a listing sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309758719/en/ AMINA, 21X and Tokeny partner for end-to-end solution Combined with AMINA’s existing collaboration with Tokeny for onchain asset issuance, the partnership creates a complete tokenisation infrastructure that addresses a major constraint of institutional adoption: the absence of an end-to-end pathway connecting regulated traditional asset c
GigaDevice Strengthens Global Presence at Embedded World 2026, Showcasing System-Level Innovations for Humanoid Robotics, Industry, and Edge AI9.3.2026 08:00:00 CET | Press release
Wide range of demonstrations on display at Hall 5, 5-129 throughout the March 10-12 show GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced its participation at Embedded World 2026 (Hall 5, Booth 5-129), with the strong presence at the show demonstrating the company’s commitment to the global market and the strategic emphasis that it has placed on the EMEA region, reinforcing its ambition to empower customers with advanced embedded solutions. “Embedded World is a cornerstone of our global engagement strategy,” said Dr. Reiner Jumpertz, GigaDevice VP and General Manager in the EMEA region. “This year, we are not only showcasing our technical excellence but also highlighting our evolution into a system-level enabler, a trusted partner that supports customers in building smarter, more connected applications.” “By combining our high-performance GD32 MCUs, industry-proven Flash memory, and a
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin9.3.2026 07:00:00 CET | Press release
Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience Delivers advanced antioxidant protection by day1 and accelerated repair by night, with visible results in as little as 7 days2 In global testing, Gallic Acid demonstrated 2x greater antioxidant efficacy than Vitamin C3 Co-developed with dermatologists and rigorously tested for sensitive skin to deliver high performance without compromising tolerance Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin. While antioxidant serums are a cornerstone of modern skincare, the category has largely been developed without sensitive sk
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
